Gastroparesis After Ozempic: Symptoms, Diagnosis, and Legal Options

Gastroparesis — sometimes called stomach paralysis — has become one of the most serious injuries at the center of the GLP-1 receptor agonist litigation. Thousands of patients who took Ozempic, Wegovy, Mounjaro, or other GLP-1 drugs for diabetes management or weight loss have reported developing severe gastroparesis, a condition that can dramatically affect quality of life and, in some cases, require hospitalization or surgery. If you are dealing with gastroparesis after taking one of these medications, this guide covers what you need to know about the condition, the legal landscape, and your options.

What Is Gastroparesis?

Gastroparesis is a condition in which the stomach loses its ability to empty food at a normal rate. In a healthy digestive system, the stomach contracts to push food into the small intestine for further digestion. When gastroparesis occurs, these contractions slow down or stop working properly, causing food to remain in the stomach for abnormally long periods.

The consequences can be severe and debilitating:

• Persistent nausea and vomiting — often the most disruptive symptoms, making it difficult to eat, work, or maintain daily routines
• Severe abdominal pain and bloating — caused by food sitting in the stomach and generating gas
• Early satiety — feeling full after only a few bites of food
• Unintentional weight loss and malnutrition — when the body cannot absorb adequate nutrition from food
• Blood sugar instability — particularly dangerous for diabetic patients, as delayed gastric emptying disrupts the timing of glucose absorption
• Dehydration — from vomiting and reduced fluid intake
• Bezoar formation — solidified masses of undigested food that can cause blockages

Gastroparesis is a chronic condition. While symptoms can be managed with dietary changes, medications, and in some cases surgical intervention, many patients experience lasting effects that fundamentally alter their daily lives.

The Connection to GLP-1 Drugs

GLP-1 receptor agonists work, in part, by slowing gastric emptying. This mechanism is actually one of the reasons these drugs help with weight loss — by slowing digestion, patients feel full longer and eat less. However, this same mechanism can tip over into pathological territory, causing the stomach to slow so dramatically that it effectively stops functioning normally.

The key drugs involved in the litigation include:

• Ozempic (semaglutide injection) — prescribed for type 2 diabetes
• Wegovy (semaglutide injection) — prescribed for weight management
• Rybelsus (oral semaglutide) — prescribed for type 2 diabetes

These semaglutide-based medications are the subject of ongoing FDA safety communications.

• Mounjaro (tirzepatide) — prescribed for type 2 diabetes and weight management

Plaintiffs in the GLP-1 litigation allege that the manufacturers — primarily Novo Nordisk and Eli Lilly — knew or should have known that these drugs carried a significant risk of causing gastroparesis and other severe gastrointestinal injuries, and that they failed to provide adequate warnings to patients and prescribing physicians.

The Gastric Emptying Study: A Critical Piece of Evidence

If you suspect you have gastroparesis after taking a GLP-1 drug, one of the most important steps you can take — both for your health and for any potential legal claim — is to undergo a gastric emptying study (GES).

A gastric emptying study, also called gastric emptying scintigraphy, is the gold standard diagnostic test for gastroparesis. During the test, you eat a meal containing a small amount of radioactive material, and a scanner tracks how quickly the food moves through your stomach over a period of several hours. The results provide an objective measurement of your gastric motility.

Why this matters for your case: In the GLP-1 litigation, cases supported by a documented gastric emptying study showing delayed gastric emptying are considered significantly stronger. The study provides objective, quantifiable evidence that your stomach motility is impaired — evidence that is difficult to dispute. If your doctor has diagnosed you with gastroparesis based on symptoms alone, ask about getting a formal GES to confirm the diagnosis.

For a comprehensive overview of the GLP-1 litigation, visit our Ozempic lawsuit page.

Do You Qualify for a Claim?

You may qualify to file a GLP-1 gastroparesis claim if you meet the following criteria:

• You took a GLP-1 receptor agonist. This includes Ozempic, Wegovy, Rybelsus, Mounjaro, or similar medications.
• You developed gastroparesis or severe gastrointestinal injury. This includes diagnosed gastroparesis, intestinal obstruction, severe cyclic vomiting requiring medical treatment, or related conditions.
• You have supporting medical documentation. Medical records showing your prescription history and your diagnosis are essential. A gastric emptying study result strengthens your case considerably.
• You are not already represented. You must not currently have an attorney handling a GLP-1 claim on your behalf.

Other serious injuries that may qualify include pancreatitis, gallbladder disease requiring surgery, bowel obstruction, and emerging claims related to vision loss (non-arteritic anterior ischemic optic neuropathy, or NAION).

What to Do Next

If you believe you developed gastroparesis from a GLP-1 medication, here are the steps to take:

1. Continue working with your doctor. Your health comes first. Follow your gastroenterologist’s treatment plan and ensure your condition is being properly monitored and documented.

2. Request a gastric emptying study. If you have not already had one, ask your doctor to order a GES. This single test can make a meaningful difference in the strength of your legal claim.

3. Gather your records. Collect your prescription history (pharmacy records), gastroenterology records, hospital records, and any documentation of how gastroparesis has affected your daily life and ability to work.

4. Consult an attorney. A legal evaluation is free and confidential. An attorney experienced in GLP-1 litigation can assess your case, explain the process, and help you understand what to expect.

5. Act within the deadline. Statutes of limitations vary by state but impose firm cutoffs on when you can file. Do not assume you have unlimited time.

Attorney Analysis

Gastroparesis cases are among the strongest in the GLP-1 litigation, particularly when supported by a gastric emptying study. The reason is straightforward: the study provides objective evidence of the exact injury that the drug’s mechanism of action is known to cause. When we evaluate cases, a confirmed GES showing delayed emptying combined with documented GLP-1 prescription history creates a clear and compelling narrative. What we tell prospective clients is this — if you are experiencing symptoms of gastroparesis and have not yet had a gastric emptying study, getting that test done now serves both your medical interests and your legal interests. The litigation is progressing toward bellwether trials in MDL 3094, and cases with strong diagnostic evidence will be best positioned as the process moves forward.

Take the Next Step

Gastroparesis is a serious, life-altering condition. If a GLP-1 medication caused your suffering, you should not have to bear the consequences alone. Understanding your legal rights is the first step toward accountability and recovery.

If you’ve been affected, request a free case review today.